Citigroup maintains Sana Biotechnology at Buy, lowers price target to $11 from $12

Citigroup kept its Buy rating on Sana Biotechnology but reduced its price target from $12 to $11, an 8.3% cut. The new target suggests a 444.6% upside from the Nov 13 closing price of $2.02, according to the bank.

Original reporting
Published Nov 16, 2026, 6:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Sana Biotechnology at Buy, lowers price target to $11 from $12 — source image
Decision brief

The 30-second read

$SANABearishMed
01

Why it matters

A price‑target reduction typically signals lower near‑term expectations and can trigger sell pressure.

02

Market read

Analyst target revisions are actionable for traders monitoring biotech stocks.

03

What to watch

Potential pipeline milestones not reflected in the target revision.

Relevance 6/10Novelty 6/10Timing: today

Background

The article reports a recent analyst rating change for Sana Biotechnology.

Company-level read

Ticker impact

$SANABearishHigh confidence
Context

Citigroup lowered its price target for Sana Biotechnology to $11 from $12, indicating a fresh analyst downgrade.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

Analyst price‑target revisions are a direct catalyst that can move the share price in the short term.

Market effects

May weigh on other biotech stocks as analysts reassess valuation multiples.

Limited to US biotech sector.

Minimal global impact.

Counterpoint

The target cut could be overly cautious if upcoming trial data exceeds expectations.

Key entities

  • Citigroup

    Maintained Buy rating but lowered price target.

  • Sana Biotechnology

    Subject of the analyst rating update.

Related articles

$SANAMed

Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.

$SANAHigh

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on pu

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

$SANAMed

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu